Haduvio™

We are developing the investigational therapy Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.

Passionate about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Passionate about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions

We are developing the investigational therapy Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its differentiated dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients.

Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients

news

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update

05/13/2021

Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

05/06/2021

Conference Call and Webcast to be Held at 4:30 p.m. ET

contact

Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510
map

(203) 304-2499
email us